Literature DB >> 15930297

Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.

Kiichiro Beppu1, Katsuya Nakamura, W Marston Linehan, Annamaria Rapisarda, Carol J Thiele.   

Abstract

The extent of angiogenesis and/or vascular endothelial growth factor (VEGF) expression in neuroblastoma tumors correlates with metastases, N-myc amplification, and poor clinical outcome. Understanding the mechanisms regulating VEGF expression in neuroblastoma cells provides additional therapeutic options to control neuroblastoma tumor growth. VEGF mRNA is controlled by growth factors and hypoxia via the transcription factor hypoxia-inducible factor (HIF-1alpha). HIF-1alpha protein levels are regulated by the von Hippel Lindau tumor suppressor gene, VHL, which targets HIF-1alpha degradation. To determine whether the levels of VEGF in neuroblastomas are due to mutations in VHL, we evaluated genomic DNA from 15 neuroblastoma cell lines using PCR. We found no mutations in exons 1, 2, or 3 of the VHL gene. VEGF mRNA levels in neuroblastoma cells cultured in serum-free medium increased after 8 to 16 hours in serum, insulin-like growth factor-I (IGF-I), epidermal growth factor, or platelet-derived growth factor. Serum/IGF-I induced increases in HIF-1alpha protein that temporally paralleled increases in VEGF mRNA, whereas HIF-1beta levels were unaffected. VEGF and HIF-1alpha levels were blocked by inhibitors of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Furthermore, we confirmed that HIF-1alpha mediates approximately 40% of the growth factor activity stimulating VEGF protein expression. Topotecan blocked the IGF-I-stimulated increase in HIF-1alpha but not HIF-1beta, and this resulted in a decrease in VEGF in four neuroblastoma cell lines tested. These data indicate that growth factors in an autocrine or paracrine manner play a major role in regulating VEGF levels in neuroblastoma cells and that targeted therapies to phosphatidylinositol 3-kinase, mammalian target of rapamycin, and/or HIF-1alpha have the potential to inhibit VEGF expression and limit neuroblastoma tumor growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930297     DOI: 10.1158/0008-5472.CAN-04-3332

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Metabolic control of the Treg/Th17 axis.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

2.  Associations between genetic polymorphisms of insulin-like growth factor axis genes and risk for age-related macular degeneration.

Authors:  Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

3.  Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.

Authors:  Sushil Kumar; Reza Bayat Mokhtari; Indhira Dias Oliveira; Syed Islam; Silvia Regina Caminada Toledo; Herman Yeger; Sylvain Baruchel
Journal:  Transl Oncol       Date:  2013-08-01       Impact factor: 4.243

4.  Association of growth factors, HIF-1 and NF-κB expression with proteasomes in endometrial cancer.

Authors:  Ludmila V Spirina; Nataliya V Yunusova; Irina V Kondakova; Larisa A Kolomiets; Valeriya D Koval; Alena L Chernyshova; Olga V Shpileva
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

5.  Hypoxia-inducible factors: a central link between inflammation and cancer.

Authors:  Daniel Triner; Yatrik M Shah
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

6.  HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.

Authors:  Yun Jung Choi; Jin Kyung Rho; Sun Joo Lee; Won Seok Jang; Seung Sook Lee; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-15       Impact factor: 4.553

7.  Targeted therapy in ovarian cancer.

Authors:  Lyndsay J Willmott; John P Fruehauf
Journal:  J Oncol       Date:  2010-01-14       Impact factor: 4.375

8.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Authors:  J Kang; P G Rychahou; T A Ishola; J M Mourot; B M Evers; D H Chung
Journal:  Oncogene       Date:  2008-02-18       Impact factor: 9.867

9.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

10.  Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells.

Authors:  Xu-dong Tang; Xin Zhou; Ke-yuan Zhou
Journal:  Acta Pharmacol Sin       Date:  2009-04-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.